Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 26.0 %

Shares of NASDAQ:EGRX opened at $0.71 on Friday. The business’s fifty day moving average price is $1.28 and its two-hundred day moving average price is $3.44. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $8.47.

Institutional Trading of Eagle Pharmaceuticals

A number of large investors have recently bought and sold shares of EGRX. Creative Planning bought a new stake in Eagle Pharmaceuticals in the third quarter valued at $59,000. Mackenzie Financial Corp bought a new stake in Eagle Pharmaceuticals in the second quarter valued at $60,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eagle Pharmaceuticals in the second quarter valued at $65,000. Fidelis Capital Partners LLC bought a new stake in Eagle Pharmaceuticals in the second quarter valued at $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Eagle Pharmaceuticals in the second quarter valued at $76,000. 85.36% of the stock is currently owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.